Imatinib Dr. Reddy’s (Imatinib)

Imatinib binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing phosphorylation of downstream proteins. This blocks signals that promote uncontrolled cell growth, induces cell‑cycle arrest, and triggers apoptosis of malignant cells that rely on these pathways.

The exact dose of Imatinib Dr. Reddy’s is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and any concomitant therapies. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for Imatinib in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the Imatinib Dr. Reddy’s product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imatinib was the first targeted tyrosine‑kinase inhibitor approved for CML and remains a standard first‑line option. Newer agents such as dasatinib or nilotinib may offer faster molecular responses in some patients, but Imatinib’s long‑term safety profile and extensive clinical experience make it a widely used and cost‑effective choice.

Imatinib Dr. Reddy’s tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Imatinib Dr. Reddy’s is taken orally, usually as a whole tablet swallowed with water. It can be taken with or without food, but patients should follow any specific instructions from their prescriber regarding timing and whether to avoid certain foods or antacids.

Serious adverse events include severe neutropenia, hepatotoxicity, cardiac dysfunction, pulmonary hypertension, and rare skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for blood‑count changes, liver enzyme elevations, and cardiac symptoms, and any concerning signs should be reported promptly.

Imatinib is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is also advised for patients with pre‑existing severe liver impairment, uncontrolled cardiac disease, or those who are pregnant or breastfeeding unless the benefits clearly outweigh the risks.